Bone Biologics Corporation (BBLG) jumped 37.20 percent to $2.84 on Thursday, gaining $0.77, after the company released a shareholder letter from President and CEO Jeffrey Frelick. The orthobiologics developer, which focuses on spine fusion markets, did not disclose new financials but highlighted its ongoing initiatives and progress in advancing its product pipeline. The stock opened at $2.75 and moved between $2.51 and $4.13 during the session, compared with a prior close of $2.07 on the New York Stock Exchange. Trading volume surged to 111.8 million shares, far exceeding the average of 511,306. Shares of Bone Biologics are trading above their 52-week low of $2.03 but remain well below the high of $16.50.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.